The Multiple Myeloma (MM) market was impacted by newly diagnosed and relapsed / refractory data presented during the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for DARZALEX® (daratumumab) (IV and SQ), VELCADE® (bortezomib), REVLIMID® (lenalidomide), KYPROLIS® (carfilzomib), XPOVIO®, (selinexor), AMG 420, and iberdomide.

Companies presenting data included: Amgen, Abbvie, Celgene, Janssen, Karyopharm, Sanofi, Takeda.

Get immediate access to this 62-slide report so you can make better decisions today and prepare for tomorrow.

Multiple Myeloma Report ASCO 2019

American Society of Clinical Oncology

Chicago, IL
May 31 to Jun 4

Share: